Beverly Hills Private Wealth LLC Sells 8,797 Shares of Johnson & Johnson $JNJ

Key Points

• Beverly Hills Private Wealth LLC reduced its Johnson & Johnson stake by 38.2% in the second quarter, selling 8,797 shares and retaining 14,225 shares valued at approximately $3.6 million. Institutional investors collectively own 69.55% of J&J.
• J&J received regulatory boosts for its oral psoriasis drug Icotyde in China and Imaavy for warm autoimmune hemolytic anemia in the U.S., while newer products are helping offset pressure from the STELARA patent loss.
• The stock has a “Moderate Buy” consensus rating with an average price target of $268.22. J&J recently exceeded quarterly earnings and revenue estimates and declared a quarterly dividend of $1.34, equivalent to a 2.0% yield.

Beverly Hills Private Wealth LLC cut its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 38.2% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 14,225 shares of the company's stock after selling 8,797 shares during the period. Beverly Hills Private Wealth LLC's holdings in Johnson & Johnson were worth $3,613,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Blueline Advisors LLC acquired a new stake in shares of Johnson & Johnson during the 4th quarter worth approximately $25,000. Cresta Advisors Ltd. bought a new position in Johnson & Johnson during the fourth quarter worth $26,000. Bay Harbor Wealth Management LLC grew its holdings in Johnson & Johnson by 49.0% in the fourth quarter. Bay Harbor Wealth Management LLC now owns 149 shares of the company's stock worth $31,000 after purchasing an additional 49 shares during the period. Semmax Financial Advisors Inc. increased its stake in Johnson & Johnson by 55.0% in the second quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company's stock valued at $31,000 after purchasing an additional 72 shares in the last quarter. Finally, E Fund Management Hong Kong Co. Ltd. increased its stake in Johnson & Johnson by 946.7% in the fourth quarter. E Fund Management Hong Kong Co. Ltd. now owns 157 shares of the company's stock valued at $32,000 after purchasing an additional 142 shares in the last quarter. Institutional investors own 69.55% of the company's stock.

Key Headlines Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: China approved J&J’s oral psoriasis pill, Icotyde, expanding the company’s immunology portfolio and giving it a simpler treatment option to compete with rival products from Bristol Myers Squibb and AbbVie. The pill could also broaden J&J’s presence in China, although it may compete with the company’s established injectable Tremfya franchise. China approves J&J's oral psoriasis pill
• Positive Sentiment: The FDA expanded approval of Imaavy for warm autoimmune hemolytic anemia in patients 12 and older who are receiving or have previously received steroids. As the first approved treatment for this rare, potentially life-threatening disorder, Imaavy addresses an unmet need and could support J&J’s rare-disease growth strategy. Imaavy expands into rare blood disorder
• Positive Sentiment: Recent analysis points to a favorable shift in J&J’s product mix, with newer products increasingly offsetting pressure from the STELARA patent loss. This supports the view that growth in the broader Innovative Medicine portfolio may be more important than the shrinking contribution from STELARA. Did a product swap fuel JNJ stock's surge?
• Positive Sentiment: Investors continue to view JNJ as a defensive dividend holding, supported by its balance sheet, diversified healthcare operations and ability to generate dependable returns through economic cycles. Johnson & Johnson is a top dividend stock

Analyst Ratings Changes

A number of equities analysts have recently issued reports on JNJ shares. Wall Street Zen cut shares of Johnson & Johnson from a "buy" rating to a "hold" rating in a research report on Saturday, August 1st. Stifel Nicolaus set a $260.00 price target on Johnson & Johnson in a research note on Wednesday, July 15th. Morgan Stanley increased their price target on Johnson & Johnson from $284.00 to $294.00 and gave the stock an "overweight" rating in a report on Thursday, July 16th. Wells Fargo & Company boosted their price objective on Johnson & Johnson from $272.00 to $282.00 and gave the company an "overweight" rating in a report on Monday, August 3rd. Finally, Argus set a $300.00 target price on Johnson & Johnson in a research report on Wednesday, July 29th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $268.22.

Insider Transactions at Johnson & Johnson

In other news, EVP Vanessa Broadhurst sold 23,054 shares of the company's stock in a transaction on Monday, July 20th. The stock was sold at an average price of $251.27, for a total transaction of $5,792,778.58. Following the transaction, the executive vice president owned 23,003 shares of the company's stock, valued at $5,779,963.81. This represents a 50.06% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Elizabeth Forminard sold 15,918 shares of the stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $257.00, for a total value of $4,090,926.00. Following the transaction, the executive vice president owned 16,994 shares of the company's stock, valued at $4,367,458. The trade was a 48.37% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 63,972 shares of company stock valued at $16,245,605. Corporate insiders own 0.16% of the company's stock.

Johnson & Johnson Stock Performance

Shares of JNJ stock opened at $268.30 on Friday. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.81 and a current ratio of 1.09. The firm has a market cap of $646.58 billion, a price-to-earnings ratio of 31.09, a P/E/G ratio of 2.56 and a beta of 0.24. Johnson & Johnson has a 52 week low of $173.33 and a 52 week high of $276.47. The firm's 50-day simple moving average is $258.88 and its two-hundred day simple moving average is $243.94.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its earnings results on Wednesday, July 15th. The company reported $2.90 earnings per share for the quarter, beating analysts' consensus estimates of $2.84 by $0.06. The firm had revenue of $25.31 billion during the quarter, compared to the consensus estimate of $25.06 billion. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.42%. The company's revenue was up 6.6% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.77 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. As a group, equities analysts forecast that Johnson & Johnson will post 11.61 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 8th. Shareholders of record on Tuesday, August 25th will be given a $1.34 dividend. This represents a $5.36 dividend on an annualized basis and a yield of 2.0%. The ex-dividend date of this dividend is Tuesday, August 25th. Johnson & Johnson's dividend payout ratio (DPR) is currently 62.11%.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company's pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source